ArticleEClinicalMedicine2025

De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trial.

Hong Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.